

FIGURE 1





FIGURE 2



2/28

FIGURE 3





FIGURE 4A



3/28

FIGURE 4B

H3W specificity and cross activity





FIGURE 5A

hPDL1-Fc



4/28

FIGURE 5B





FIGURE 6A

hPDL1-Fc



5/28

FIGURE 6B

msPDL1-Fc




FIGURE 6C

hCD28-Fc






FIGURE 6D

hB7-1



6/28

FIGURE 7



	Human	Mouse	Cynomolgus
K_d nM	0.5150	0.6657	0.3994

FIGURE 8A





FIGURE 8B



8/28

FIGURE 9A




Mouse

FIGURE 9B

Cyno

9/28

FIGURE 9C

Human**affinity to hPDL1/Fc**

	Kd (nM)	
	C5H9	C5H9v2
Mouse	0.4754	0.4637
Cyno	0.3981	0.5439
Human	0.2865	0.2716

10/28

FIGURE 10





FIGURE 11



12/28

FIGURE 12



C5H9 vs 10F9G2 (Multiple Doses)

FIGURE 13

**Anti-PDL1 in 9 Week Old
Female NOD Mice
C14-055 - C5H9v2 Dose Titration**

13/28

FIGURE 14






FIGURE 15A



14/28


FIGURE 15B



	Masking Efficiency		
	Media	Purified	
	Human	Human	Mouse
PL02	12	80	650
PL03	5	2	5
PL04	52	70	574
PL06	23	16	259
PL07	38	37	389

15/28


FIGURE 16



Mask efficiency	PL09	PL10	PL11	PL12	PL13	PL14	PL15
hPDL1	31	63	12	88	1.4	26	2
mPDL1	1518	2246	251	2940	4	1012	48

FIGURE 17

hPDL-1/Fc binding



ME	PL16	PL17	PL18	PL19	PL20	PL23	PL03+	PL03-
hPDL1	88	7.2	1.0	56	18.3	77.7	0.6	1.1
mPDL1	n/a	421	25	954	645	n/a	1	2.2

17/28

FIGURE 18A





FIGURE 18B

**C15-002 PD-L1 Pb
in 9 wk old Female NOD Mice**



18/28

FIGURE 19





FIGURE 20A

Transform of Blood CD4



19/28

FIGURE 20B




FIGURE 20C




FIGURE 20D




FIGURE 21A




FIGURE 21B




FIGURE 22




FIGURE 23A




FIGURE 23B




FIGURE 23C




FIGURE 23D






FIGURE 24



23/28

FIGURE 25A


hPDL1 binding



hPDL1	PL-2001	PL-3001
ME	25	21

FIGURE 25B


mPDL1_binding



mPDL1	PL-2001	PL-3001
ME	510	450


24/28

FIGURE 26A



	C5H9v2	PL07-2001 C5H9v2 + UPA	PL07-2001 C5H9v2 + MMP	PL07-2001 C5H9v2
IC ₅₀ (nM)	0.7	0.7	0.7	39.8
ME	1	1	1	57


FIGURE 26B



	C5H9v2	PL07-2001 C5H9v2 + UPA	PL07-2001 C5H9v2 + MMP	PL07-2001 C5H9v2
IC ₅₀ (nM)	0.3	0.3	0.3	7
ME	1	1	1	23


25/28

FIGURE 26C



	C5H9v2	PL07-2001 C5H9v2 + UPA	PL07-2001 C5H9v2 + MMP	PL07-2001 C5H9v2
IC ₅₀ (nM)	0.3	0.3	0.3	11.9
ME	1	1	1	40


FIGURE 27A



	C5H9v2	PL07-2001 C5H9v2 + UPA	PL07-2001 C5H9v2 + MMP	PL07-2001 C5H9v2
IC ₅₀ (nM)	0.5	0.5	0.4	11.7
ME	1	1	1	29


26/28

FIGURE 27B



	C5H9v2	PL07-2001 C5H9v2 + UPA	PL07-2001 C5H9v2 + MMP	PL07-2001 C5H9v2
IC50 (nM)	0.1	0.1	0.1	9.6
ME	1	1	1	96


FIGURE 28




27/28

FIGURE 29A


CD4+ Antigen Occupancy correlation Exposure



CD8+ Antigen Occupancy correlation Exposure

**FIGURE 29B**

CD4+ Antigen Occupancy correlation Exposure



CD8+ Antigen Occupancy correlation Exposure




FIGURE 29C




FIGURE 30

